Drug Search Results
More Filters [+]

Propyphenazone

Alternative Names: propyphenazone
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: COX Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Brazil | Bulgaria | Chile | China | Dominican Republic | Egypt | Hong Kong | Hungary | India | Indonesia | Italy | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Spain | Taiwan | Turkey | Ukraine | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Propyphenazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Acute Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-001069-17

P4

Completed

Acute Pain

2005-03-06

Recent News Events